clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2021-3-31-38clinvest-584Research ArticleБЕЗОПАСНОСТЬ ЛЕКАРСТВDRUG SAFETYВзаимодействие пищевых продуктов и лекарственных средств как фактор риска развития лекарственно индуцированных заболеваний: эпидемиология, факторы риска, потенциальные механизмы развития взаимодействийFood-drug interaction as a risk factor of drug-induced diseases: epidemiology, risk factors, potential mechanisms of interactionhttps://orcid.org/0000-0001-7168-3636ПереверзевА. П.PereverzevA. P.

Переверзев Антон Павлович, к. м. н., доцент кафедры терапии и полиморбидной патологии

SPIN-код: 4842-3770

Москва 

Pereverzev Anton P., Cand. Sci. Med., Associate Professor of the Department of Therapy and Polymorbid Pathology 

SPIN code: 4842-3770

Moscow

terapia_polimorbid@rmapo.ruhttps://orcid.org/0000-0002-0795-8225ОстроумоваО. Д.OstroumovaO. D.

Остроумова Ольга Дмитриевна, д. м. н., профессор, зав. кафедрой терапии и полиморбидной патологии; профессор кафедры клинической фармакологии и пропедевтики внутренних болезней 

SPIN-код: 3910-6585

Москва 

Ostroumova Olga D., Dr. Sci. (Med.), professor, head of the Department of Therapy and Polymorbid Pathology; professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases 

SPIN code: 3910-6585

Moscow

ostroumova.olga@mail.ruФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФРоссияFSBEI FPE «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ; ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава Российской Федерации (Сеченовский университет)РоссияFSBEI FPE «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation; FSAEI HE I.M. Sechenov First MSMU MOH Russia (Sechenovskiy University)Russian Federation202108122021033138Copyright © Переверзев А.П., Остроумова О.Д., 20212021Переверзев А.П., Остроумова О.Д.Pereverzev A.P., Ostroumova O.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/584

Введение любого лекарственного средства (ЛС) потенциально ассоциировано с риском развития нежелательных реакций (НР), частота возникновения которых в развитых и развивающихся странах оценивается в 6,3 (3,3—11,0) и 5,5 % (1,1—16,9) соответственно. Многие НР повышают смертность и/или заболеваемость и/или становятся причиной возникновения клинических проявлений, требующих обращения пациента за медицинской помощью или госпитализации. Был введён специальный термин — «лекарственно индуцированные заболевания» (англ. druginduced diseases). Продукты питания могут взаимодействовать с ЛС и повышать риски развития НР, в том числе серьёзных НР. Приём как пищи в целом, так и определённых продуктов питания одновременно с некоторыми лекарствами может влиять на общую биодоступность, фармакокинетику, фармакодинамику и терапевтическую эффективность лекарств за счёт изменений абсорбции и метаболизма ЛС. Ярким примером влияния пищи на фармакокинетический профиль ЛС является изменение биодоступности ингибитора тирозинкиназы лапатиниба: по сравнению с приёмом натощак биодоступность лапатиниба в разовой дозе 1 500 мг после приёма его вместе с высококалорийной стандартной пищей увеличивается в среднем на 325 % — в 4,25 раза. Другими словами, концентрация препарата в сыворотке крови после приёма одной таблетки одновременно с пищей сопоставима с приёмом 4 таблеток натощак. В настоящее время отсутствуют рекомендации по выбору режима дозирования ЛС в зависимости от качественного и количественного состава пищи, а также учитывающего потенциальные взаимодействия с компонентами пищи, хотя данные рекомендации крайне необходимы пациентам и специалистам практического здравоохранения. В связи с этим в данной статье суммированы имеющиеся на момент написания в открытых источниках данные, касающиеся влияния продуктов питания на абсорбцию и метаболизм ЛС, а также описаны возможные механизмы взаимодействия.

Any drug is potentially associated with the risk of adverse drug reactions (ADRs), the incidence of which in developed and developing countries is estimated at 6.3 (3.3—11.0) and 5.5 % (1.1—16.9), respectively. Many ADRs increase mortality and / or morbidity and / or cause clinical manifestations that require a patient to seek medical help or hospitalization; a special term has been introduced — drug-induced diseases. Food can interact with drugs and increase the risk of ADRs, including serious ones. The simultaneous intake of food and drugs can affect the bioavailability, pharmacokinetics, pharmacodynamics and therapeutic efficacy of drugs due to changes in drug absorption and metabolism. A striking example of the effect of food on the pharmacokinetic profile of drugs is the change in the bioavailability of the tyrosine kinase inhibitor lapatinib: compared with taking on an empty stomach, the bioavailability of lapatinib in a single dose of 1 500 mg after taking it together with high-calorie standard food increases by an average of 325 % — 4.25 times. In other words, the concentration of the drug in the blood serum after taking one tablet at the same time with food is comparable to taking 4 tablets on an empty stomach. Currently, there are no recommendations for choosing a dosage regimen for drugs depending on the qualitative and quantitative composition of food, as well as taking into account potential interactions with food components, although these recommendations are extremely necessary for patients and healthcare professionals. In this regard, this article summarizes the data available at the time of writing in open sources concerning the effect of food on the absorption and metabolism of drugs, and also describes the possible mechanisms of interaction.

лекарственные средстванежелательные реакциилекарственно индуцированные заболеваниявзаимодействия «лекарство-пища»drugsadverse drug reactionsdrug-induced diseasesfood-drug interactionReferencesСычёв Д. А., Остроумова О. Д., Кочетков А. И., Переверзев А. П., Остроумова Т. М., Клепикова М. В., Аляутдинова И. А., Эбзеева Е. Ю. Лекарственноиндуцированные заболевания: эпидемиология и актуальность проблемы. Фарматека. 2020;27(5):77–84. [Sychev DA, Ostroumova OD, Kochetkov AI, Pereverzev AP, Ostroumova TM, Klepikova MV, Alyautdinova IA, Ebzeeva EYu. Drug-induced diseases: epidemiology and urgency of the problem. Pharmateca. 2020;27(5):77–84. (In Russ).]Сычёв Д. А., Остроумова О. Д., Кочетков А. И., Переверзев А. П., Остроумова Т. М., Клепикова М. В., Аляутдинова И. А., Эбзеева Е. Ю. Лекарственноиндуцированные заболевания: эпидемиология и актуальность проблемы. Фарматека. 2020;27(5):77–84. [Sychev DA, Ostroumova OD, Kochetkov AI, Pereverzev AP, Ostroumova TM, Klepikova MV, Alyautdinova IA, Ebzeeva EYu. Drug-induced diseases: epidemiology and urgency of the problem. Pharmateca. 2020;27(5):77–84. (In Russ).]Hakkarainen KM, Gyllensten H, Jonsson AK, et al. Prevalence, nature and potential preventability of adverse drug events: a population-based medical record study of 4970 adults. Br J Clin Pharmacol. 2014;78(1):170–83. doi: 10.1111/bcp.12314.Hakkarainen KM, Gyllensten H, Jonsson AK, et al. Prevalence, nature and potential preventability of adverse drug events: a population-based medical record study of 4970 adults. Br J Clin Pharmacol. 2014;78(1):170–83. doi: 10.1111/bcp.12314.Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of HealthSystem Pharmacists; 2018; 1399 рр.Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of HealthSystem Pharmacists; 2018; 1399 рр.Сычев Д. А., Остроумова О. Д., Переверзев А. П., Кочетков А. И., Остроумова Т. М., Клепикова М. В., Эбзеева Е. Ю. Пожилой и старческий возраст пациентов как фактор риска развития лекарственно-индуцированных заболеваний. Безопасность и риск фармакотерапии. 2021;9(1):15– 24. [Sychev DA, Ostroumova OD, Pereverzev AP, Kochetkov AI, Ostroumova TM, Klepikova MV, Ebzeeva EYu. Advanced age as a risk factor of drug-induced diseases. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2021;9(1):15–24. (In Russ).]. doi: 10.30895/2312-7821-2021-9-1-15-24Сычев Д. А., Остроумова О. Д., Переверзев А. П., Кочетков А. И., Остроумова Т. М., Клепикова М. В., Эбзеева Е. Ю. Пожилой и старческий возраст пациентов как фактор риска развития лекарственно-индуцированных заболеваний. Безопасность и риск фармакотерапии. 2021;9(1):15– 24. [Sychev DA, Ostroumova OD, Pereverzev AP, Kochetkov AI, Ostroumova TM, Klepikova MV, Ebzeeva EYu. Advanced age as a risk factor of drug-induced diseases. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2021;9(1):15–24. (In Russ).]. doi: 10.30895/2312-7821-2021-9-1-15-24Сычёв Д. А., Остроумова О. Д., Переверзев А. П., Кочетков А. И., Остроумова Т. М., Клепикова М. В., Эбзеева Е. Ю. Женский пол как фактор риска развития лекарственно-индуцированных заболеваний. Безопасность и риск фармакотерапии. 2021;9(2):85–94. [Sychev DA, Ostroumova OD, Pereverzev AP, Kochetkov AI, Ostroumova TM, Klepikova MV, Ebzeeva EYu. Female gender as a risk factor for drug-induced diseases. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2021;9(2):85–94. (In Russ).]. doi: 10.30895/2312-7821-2021-9-2-85-94Сычёв Д. А., Остроумова О. Д., Переверзев А. П., Кочетков А. И., Остроумова Т. М., Клепикова М. В., Эбзеева Е. Ю. Женский пол как фактор риска развития лекарственно-индуцированных заболеваний. Безопасность и риск фармакотерапии. 2021;9(2):85–94. [Sychev DA, Ostroumova OD, Pereverzev AP, Kochetkov AI, Ostroumova TM, Klepikova MV, Ebzeeva EYu. Female gender as a risk factor for drug-induced diseases. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2021;9(2):85–94. (In Russ).]. doi: 10.30895/2312-7821-2021-9-2-85-94Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, Hoad CL, Jedamzik P, Madla CM, Maliepaard M, Marciani L, Maruca A, Parrott N, Pávek P, Porter CJH, Reppas C, van Riet-Nales D, Rubbens J, Statelova M, Trevaskis NL, Valentová K, Vertzoni M, Čepo DV, Corsetti M. The mechanisms of pharmacokinetic food-drug interactions — A perspective from the UNGAP group. Eur J Pharm Sci. 2019 Jun 15;134:31–59. doi: 10.1016/j.ejps.2019.04.003Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, Hoad CL, Jedamzik P, Madla CM, Maliepaard M, Marciani L, Maruca A, Parrott N, Pávek P, Porter CJH, Reppas C, van Riet-Nales D, Rubbens J, Statelova M, Trevaskis NL, Valentová K, Vertzoni M, Čepo DV, Corsetti M. The mechanisms of pharmacokinetic food-drug interactions — A perspective from the UNGAP group. Eur J Pharm Sci. 2019 Jun 15;134:31–59. doi: 10.1016/j.ejps.2019.04.003Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010;16(17):4446–51. doi: 10.1158/1078-0432.ccr-10-0663Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010;16(17):4446–51. doi: 10.1158/1078-0432.ccr-10-0663Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016 Jun;21(6):962– 76. doi: 10.1016/j.drudis.2016.03.002Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016 Jun;21(6):962– 76. doi: 10.1016/j.drudis.2016.03.002Abdollahi M, Eslami S, Taherzadeh Z, Salehi S, Ebrahimi M. Factors Associated with Potential Food-Drug Interaction in Hospitalized Patients: A Cross-Sectional Study in Northeast Iran. Evidence Based Care. 2018;8(1):27–34. doi: 10.22038/EBCJ.2018.24726.1544Abdollahi M, Eslami S, Taherzadeh Z, Salehi S, Ebrahimi M. Factors Associated with Potential Food-Drug Interaction in Hospitalized Patients: A Cross-Sectional Study in Northeast Iran. Evidence Based Care. 2018;8(1):27–34. doi: 10.22038/EBCJ.2018.24726.1544Carvalho REFLd, Reis AMM, Faria LMPd, Zago KSdA, Cassiani SHDB. Prevalence of drug interactions in intensive care units in Brazil. Acta Paulista de Enfermagem. 2013;26(2):150–7. doi: 10.1590/S0103-21002013000200008Carvalho REFLd, Reis AMM, Faria LMPd, Zago KSdA, Cassiani SHDB. Prevalence of drug interactions in intensive care units in Brazil. Acta Paulista de Enfermagem. 2013;26(2):150–7. doi: 10.1590/S0103-21002013000200008Neves SJF, Marques A. Prevalence and predictors of potential drugfood interactions among the elderly using prescription drugs. Journal of Chemical and Pharmaceutical Research. 2016;8(4):965–2.Neves SJF, Marques A. Prevalence and predictors of potential drugfood interactions among the elderly using prescription drugs. Journal of Chemical and Pharmaceutical Research. 2016;8(4):965–2.European Medicines Agency (EMA), 2012. Guideline on the Investigation of Drug Interactions. Committee for Human Medicinal Products (CHMP). Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-investigation-drug-interactions_en.pdf (accessed 06.08.2021).European Medicines Agency (EMA), 2012. Guideline on the Investigation of Drug Interactions. Committee for Human Medicinal Products (CHMP). Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-investigation-drug-interactions_en.pdf (accessed 06.08.2021).Food and drug Administration (FDA), 2002. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Available from. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinfor mation/guidances/ ucm070241.pdf. (accessed 06.08.2021)Food and drug Administration (FDA), 2002. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Available from. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinfor mation/guidances/ ucm070241.pdf. (accessed 06.08.2021)Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 2009;27(8):1191–6. doi: 10.1200/JCO.2008.18.3285.Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 2009;27(8):1191–6. doi: 10.1200/JCO.2008.18.3285.Фармакология: учебник / под ред. Р. Н. Аляутдина. — 5-е изд., перераб. и доп. — М.: ГЭОТАР-Медиа, 2015. — 1104 с.: ил. [Pharmacology: textbook / ed. R.N. Alyautdina. — 5th ed., Rev. and add. Moscow: GEOTARMedia, 2015. (In Russ).].Фармакология: учебник / под ред. Р. Н. Аляутдина. — 5-е изд., перераб. и доп. — М.: ГЭОТАР-Медиа, 2015. — 1104 с.: ил. [Pharmacology: textbook / ed. R.N. Alyautdina. — 5th ed., Rev. and add. Moscow: GEOTARMedia, 2015. (In Russ).].Won CS, Oberlies NH, Paine MF. Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther. 2012 Nov;136(2):186–201. doi: 10.1016/j.pharmthera.2012.08.001Won CS, Oberlies NH, Paine MF. Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther. 2012 Nov;136(2):186–201. doi: 10.1016/j.pharmthera.2012.08.001Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003 Jan 10;1609(1):1–18. doi: 10.1016/s0005-2736(02)00633–8Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003 Jan 10;1609(1):1–18. doi: 10.1016/s0005-2736(02)00633–8Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703–8. doi: 10.1124/jpet.103.051300Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703–8. doi: 10.1124/jpet.103.051300Imanaga J, Kotegawa T, Imai H, Tsutsumi K, Yoshizato T, Ohyama T, Shirasaka Y, Tamai I, Tateishi T, Ohashi K. The effects of the SLCO2B1 c.1457C < T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84–93. doi: 10.1097/fpc.0b013e32834300ccImanaga J, Kotegawa T, Imai H, Tsutsumi K, Yoshizato T, Ohyama T, Shirasaka Y, Tamai I, Tateishi T, Ohashi K. The effects of the SLCO2B1 c.1457C < T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84–93. doi: 10.1097/fpc.0b013e32834300ccTapaninen T, Neuvonen PJ, Niemi M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther. 2010 Sep;88(3):339–42. doi: 10.1038/clpt.2010.101Tapaninen T, Neuvonen PJ, Niemi M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther. 2010 Sep;88(3):339–42. doi: 10.1038/clpt.2010.101Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic aniontransporting polypeptide OATP-B. Drug Metab Dispos. 2006 Apr;34(4):577– 82. doi: 10.1124/dmd.105.007872Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic aniontransporting polypeptide OATP-B. Drug Metab Dispos. 2006 Apr;34(4):577– 82. doi: 10.1124/dmd.105.007872Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptidemediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002 Jan;71(1):11–20. doi: 10.1067/mcp.2002.121152Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptidemediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002 Jan;71(1):11–20. doi: 10.1067/mcp.2002.121152Tsui JK, Ross S, Poulin K, Douglas J, Postnikoff D, Calne S, Woodward W, Calne DB. The effect of dietary protein on the efficacy of L-dopa: a double-blind study. Neurology. 1989 Apr;39(4):549–52. doi: 10.1212/wnl.39.4.549Tsui JK, Ross S, Poulin K, Douglas J, Postnikoff D, Calne S, Woodward W, Calne DB. The effect of dietary protein on the efficacy of L-dopa: a double-blind study. Neurology. 1989 Apr;39(4):549–52. doi: 10.1212/wnl.39.4.549Koven W, Schulte P. The effect of fasting and refeeding on mRNA expression of PepT1 and gastrointestinal hormones regulating digestion and food intake in zebrafish (Danio rerio). Fish Physiol Biochem. 2012 Dec;38(6):1565–75. doi: 10.1007/s10695-012-9649-6Koven W, Schulte P. The effect of fasting and refeeding on mRNA expression of PepT1 and gastrointestinal hormones regulating digestion and food intake in zebrafish (Danio rerio). Fish Physiol Biochem. 2012 Dec;38(6):1565–75. doi: 10.1007/s10695-012-9649-6Petric Z, Žuntar I, Putnik P, Bursać Kovačević D. Food-Drug Interactions with Fruit Juices. Foods. 2020;10(1):33. Published 2020 Dec 24. doi: 10.3390/foods10010033Petric Z, Žuntar I, Putnik P, Bursać Kovačević D. Food-Drug Interactions with Fruit Juices. Foods. 2020;10(1):33. Published 2020 Dec 24. doi: 10.3390/foods10010033Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007 Aug;12(8):927–41. doi: 10.1634/theoncologist.12-8-927Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007 Aug;12(8):927–41. doi: 10.1634/theoncologist.12-8-927Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009 Feb;85(2):173–81. doi: 10.1038/clpt.2008.195Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009 Feb;85(2):173–81. doi: 10.1038/clpt.2008.195Keppler D. Multidrug Resistance Proteins (MRPs, ABCCs): Importance for Pathophysiology and Drug Therapy. Handb Exp Pharmacol. 2011;(201):299–323. doi: 10.1007/978-3-642-14541-4_8Keppler D. Multidrug Resistance Proteins (MRPs, ABCCs): Importance for Pathophysiology and Drug Therapy. Handb Exp Pharmacol. 2011;(201):299–323. doi: 10.1007/978-3-642-14541-4_8van Zanden JJ, van der Woude H, Vaessen J, Usta M, Wortelboer HM, Cnubben NH, Rietjens IM. The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochemical Pharmacology. 2007 Jul;74(2):345–51. doi: 10.1016/j.bcp.2007.04.002van Zanden JJ, van der Woude H, Vaessen J, Usta M, Wortelboer HM, Cnubben NH, Rietjens IM. The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochemical Pharmacology. 2007 Jul;74(2):345–51. doi: 10.1016/j.bcp.2007.04.002Chalet C, Rubbens J, Tack J, Duchateau GS, Augustijns P. Intestinal disposition of quercetin and its phase-II metabolites after oral administration in healthy volunteers. J Pharm Pharmacol. 2018 Aug;70(8):1002–8. doi: 10.1111/jphp.12929Chalet C, Rubbens J, Tack J, Duchateau GS, Augustijns P. Intestinal disposition of quercetin and its phase-II metabolites after oral administration in healthy volunteers. J Pharm Pharmacol. 2018 Aug;70(8):1002–8. doi: 10.1111/jphp.12929Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005 May 1;204(3):216–37. doi: 10.1016/j.taap.2004.10.012Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005 May 1;204(3):216–37. doi: 10.1016/j.taap.2004.10.012Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012;31(2):73–99. doi: 10.5732/cjc.011.10320Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012;31(2):73–99. doi: 10.5732/cjc.011.10320Friedlander G, Le Grimellec C, Amiel C. Increase in membrane fluidity modulates sodium-coupled uptakes and cyclic AMP synthesis by renal proximal tubular cells in primary culture. Biochim Biophys Acta. 1990 Feb 16;1022(1):1–7. doi: 10.1016/0005-2736(90)90393-3Friedlander G, Le Grimellec C, Amiel C. Increase in membrane fluidity modulates sodium-coupled uptakes and cyclic AMP synthesis by renal proximal tubular cells in primary culture. Biochim Biophys Acta. 1990 Feb 16;1022(1):1–7. doi: 10.1016/0005-2736(90)90393-3Arora A, Byrem TM, Nair MG, Strasburg GM. Modulation of liposomal membrane fluidity by flavonoids and isoflavonoids. Arch Biochem Biophys. 2000 Jan 1;373(1):102–9. doi: 10.1006/abbi.1999.1525Arora A, Byrem TM, Nair MG, Strasburg GM. Modulation of liposomal membrane fluidity by flavonoids and isoflavonoids. Arch Biochem Biophys. 2000 Jan 1;373(1):102–9. doi: 10.1006/abbi.1999.1525Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 «pie». Drug Metab Dispos. 2006 May;34(5):880–6. doi: 10.1124/dmd.105.008672Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 «pie». Drug Metab Dispos. 2006 May;34(5):880–6. doi: 10.1124/dmd.105.008672Galetin A, Gertz M, Houston JB. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet. 2010;25(1):28–47. doi: 10.2133/dmpk.25.28Galetin A, Gertz M, Houston JB. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet. 2010;25(1):28–47. doi: 10.2133/dmpk.25.28Информационный портал для специалистов практического здравоохранения MSD manual: Лекарственные препараты, взаимодействующие с изоферментами цитохрома P450 (дата обращения: 06.08.2021) [Informational portal for healthcare practitioners MSD manual: Drugs interacting with cytochrome P450 isoenzymes. (Accessed: 06.08.2021) (In Russ).]. Available at: https://www.msdmanuals.com/ru-ru/профессиональный/multimedia/table/v1109123_ru.Информационный портал для специалистов практического здравоохранения MSD manual: Лекарственные препараты, взаимодействующие с изоферментами цитохрома P450 (дата обращения: 06.08.2021) [Informational portal for healthcare practitioners MSD manual: Drugs interacting with cytochrome P450 isoenzymes. (Accessed: 06.08.2021) (In Russ).]. Available at: https://www.msdmanuals.com/ru-ru/профессиональный/multimedia/table/v1109123_ru.Официальный сайт Агентства по контролю за пищевыми продуктами и лекарственными средствами США: таблица субстратов, индукторов и ингибиторов изоферментов цитохрома Р450 (дата обращения: 06.08.2021) [Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers (Accessed: 06.08.2021) (In Russ).]. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-developmentand-drug-interactions-table-substrates-inhibitors-and-inducers.Официальный сайт Агентства по контролю за пищевыми продуктами и лекарственными средствами США: таблица субстратов, индукторов и ингибиторов изоферментов цитохрома Р450 (дата обращения: 06.08.2021) [Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers (Accessed: 06.08.2021) (In Russ).]. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-developmentand-drug-interactions-table-substrates-inhibitors-and-inducers.Bibi Z. Role of cytochrome P450 in drug interactions [retracted in: Nutr Metab (Lond). 2014 Feb 14;11(1):11. doi: 10.1186/1743-7075-11-11.]. Nutr Metab (Lond). 2008;5:27. Published 2008 Oct 18. doi: 10.1186/1743-7075-5-27Bibi Z. Role of cytochrome P450 in drug interactions [retracted in: Nutr Metab (Lond). 2014 Feb 14;11(1):11. doi: 10.1186/1743-7075-11-11.]. Nutr Metab (Lond). 2008;5:27. Published 2008 Oct 18. doi: 10.1186/1743-7075-5-27

The authors declare that there are no conflicts of interest present.